Interferon beta treatment for multiple sclerosis: Persisting questions

Multiple Sclerosis

Volumn 1, Issue 6, 1996, Pages 321-324

  Goodkin, Donald E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interferon beta; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA SERINE; INTERFERON BETA-1B; RECOMBINANT PROTEIN;

ANTIBODY PRODUCTION; HUMAN; MULTIPLE SCLEROSIS; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; GADOLINIUM; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0030178241     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100605     Document Type: Article

References (17)

1. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized trial. Neurology 45: 1277-1285.
2. The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter randomized double-blind, placebo-controlled trial. Neurology 43: 655-661.
3. Paty DW et al. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
4. Sibley WA et al. (1994) Interferon beta treatment of multiple sclerosis [reply to letters]. Neurology 41: 188-190.
5. Stone LA. (1995) The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 37: 611-619.
6. Jacobs L et al. (1994) Biogen's IFN beta-1a reduces progression of disability in multiple - sclerosis. First European Presentation of Phase III Trial Results. Clin Courier 12: 1-4.
7. Goodkin DE. (1994) Interferon beta-1b. Lancet 344: 1057-1060.
8. Kurtzke J.F (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
9. Kurtzke JF. (1956) Course of exacerbations of multiple sclerosis in hospitalized patients. Arch Neurol Psychiatry 76: 175-184.
10. Neilley LK et al. (1996) Side effect profile of interferon beta-1b inmultiple sclerosis: results of an open label trial. Neurology 46: 552-554.
11. McFarland HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
12. Polman CH. (1995) Interferon beta-1b in the treatment of secondary progressive multiple sclerosis. Multiple Sclerosis 1; S51-S54.
13. Sandberg-Wollheim M et al. (1995) Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 1: S48-S50.
14. Comi G et al. (1995) Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta); design of the study. Multiple Sclerosis 1: S24-S27.
15. Beck RW. (In press) Strategies to delay the onset of clinically definite MS in patients with monosymptomatic presentations of optic neuritis, brainstem syndromes, or myelopathy. In Multiple Sclerosis: Advances in clinical trial design, treatment and future perspectives Eds: Goodkin DE, Rudick RA. Springer-Verlag, London.
16. Rudick RA et al. (1995) Toxicity of recombinant intramuscular interferon-β-1a in multiple sclerosis patients. Ann Neurol 38: 313.
17. Rudge P et al. (1995) Does Interferon beta cause initial exacerbations of multiple sclerosis? Lancet 345: 580.